Cargando…
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis
BACKGROUND: Esophageal adenocarcinoma (EAC) has high mortality and is increasing in incidence. Barrett's esophagus (BE) increases the risk for EAC. Studies have reported inconsistent findings on the association between use of cyclooxygenase (COX) inhibitors and the risk of neoplastic progressio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007227/ https://www.ncbi.nlm.nih.gov/pubmed/24651385 http://dx.doi.org/10.1038/bjc.2014.127 |
_version_ | 1782314313964322816 |
---|---|
author | Zhang, S Zhang, X-Q Ding, X-W Yang, R-K Huang, S-L Kastelein, F Bruno, M Yu, X-J Zhou, D Zou, X-P |
author_facet | Zhang, S Zhang, X-Q Ding, X-W Yang, R-K Huang, S-L Kastelein, F Bruno, M Yu, X-J Zhou, D Zou, X-P |
author_sort | Zhang, S |
collection | PubMed |
description | BACKGROUND: Esophageal adenocarcinoma (EAC) has high mortality and is increasing in incidence. Barrett's esophagus (BE) increases the risk for EAC. Studies have reported inconsistent findings on the association between use of cyclooxygenase (COX) inhibitors and the risk of neoplastic progression in BE patients. Therefore, we performed a meta-analysis to investigate this association. METHODS: A meta-analysis was undertaken among a total of 9 observational studies using fixed- and random-effects models, comprising 5446 participants; 605 had EAC or high-grade dysplasia (HGD). RESULTS: Overall, COX inhibitors use was associated with a reduced risk of EAC/HGD among BE patients (relative risk (RR)=0.64, 95% confidence interval (CI)=0.53–0.77). Aspirin use also reduced the risk of EAC/HGD (RR=0.63, 95% CI=0.43–0.94), as well as non-aspirin COX inhibitors (RR=0.50, 95% CI=0.32–0.78). The chemopreventive effect seemed to be independent of duration response. CONCLUSIONS: Cyclooxygenase inhibitors use is associated with a reduced risk of developing EAC in patients with BE. Both low-dose aspirin and non-aspirin COX inhibitors are associated with a reduced risk of neoplasia. More well-designed randomised controlled trials are needed to increase our understanding of the chemopreventive effect of COX inhibitors. |
format | Online Article Text |
id | pubmed-4007227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-40072272015-04-29 Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis Zhang, S Zhang, X-Q Ding, X-W Yang, R-K Huang, S-L Kastelein, F Bruno, M Yu, X-J Zhou, D Zou, X-P Br J Cancer Epidemiology BACKGROUND: Esophageal adenocarcinoma (EAC) has high mortality and is increasing in incidence. Barrett's esophagus (BE) increases the risk for EAC. Studies have reported inconsistent findings on the association between use of cyclooxygenase (COX) inhibitors and the risk of neoplastic progression in BE patients. Therefore, we performed a meta-analysis to investigate this association. METHODS: A meta-analysis was undertaken among a total of 9 observational studies using fixed- and random-effects models, comprising 5446 participants; 605 had EAC or high-grade dysplasia (HGD). RESULTS: Overall, COX inhibitors use was associated with a reduced risk of EAC/HGD among BE patients (relative risk (RR)=0.64, 95% confidence interval (CI)=0.53–0.77). Aspirin use also reduced the risk of EAC/HGD (RR=0.63, 95% CI=0.43–0.94), as well as non-aspirin COX inhibitors (RR=0.50, 95% CI=0.32–0.78). The chemopreventive effect seemed to be independent of duration response. CONCLUSIONS: Cyclooxygenase inhibitors use is associated with a reduced risk of developing EAC in patients with BE. Both low-dose aspirin and non-aspirin COX inhibitors are associated with a reduced risk of neoplasia. More well-designed randomised controlled trials are needed to increase our understanding of the chemopreventive effect of COX inhibitors. Nature Publishing Group 2014-04-29 2014-03-20 /pmc/articles/PMC4007227/ /pubmed/24651385 http://dx.doi.org/10.1038/bjc.2014.127 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Epidemiology Zhang, S Zhang, X-Q Ding, X-W Yang, R-K Huang, S-L Kastelein, F Bruno, M Yu, X-J Zhou, D Zou, X-P Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis |
title | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis |
title_full | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis |
title_fullStr | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis |
title_full_unstemmed | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis |
title_short | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis |
title_sort | cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with barrett's esophagus: a meta-analysis |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007227/ https://www.ncbi.nlm.nih.gov/pubmed/24651385 http://dx.doi.org/10.1038/bjc.2014.127 |
work_keys_str_mv | AT zhangs cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis AT zhangxq cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis AT dingxw cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis AT yangrk cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis AT huangsl cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis AT kasteleinf cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis AT brunom cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis AT yuxj cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis AT zhoud cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis AT zouxp cyclooxygenaseinhibitorsuseisassociatedwithreducedriskofesophagealadenocarcinomainpatientswithbarrettsesophagusametaanalysis |